Perspective Therapeutics filed an update on its Phase 1/2a melanoma trial, but this filing gives no patient outcomes or safety findings. It does not show whether the treatment is helping or harming the company's outlook.
To judge the treatment's promise, readers need to know how patients responded and what side effects occurred. The supplied filing gives neither, so this update does not show a change in the company's prospects.
Follow Perspective Therapeutics, Inc. (CATX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CATX